Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Oncocyte Shot 13% Higher Today

TheMotleyFool

0 0

Cancer diagnostics specialist Oncocyte (NYSEMKT: OCX) rose at a double-digit pace on Friday on news that it's tapping the stock market for a new round of capital-raising.

Oncocyte priced its previously announced underwritten secondary stock issue of 7.78 million shares at $4.50 apiece. If all goes well, this should bring in gross proceeds of roughly $35 million. The underwriters have a 30-day option to buy nearly 1.17 million additional shares at the offering price. The issue should close on or about Tuesday, Feb. 9.

Source Fool.com

Like: 0

OCX

Share